Publications

2025

1. Oshima M, Takayama N, Nakajima-Takagi Y, Shinoda D, Itokawa N, Kurosawa S, Kaito S, Kamiya T, Yamada Y, Andoh S, Kayamori K, Paul SK, Kanashiro MA, Muto T, Tsukamoto S, Sakaida E, Sato E, Yusa N, Yokoyama K, Nannya Y, Imoto S, Rahmutulla B, Kaneda A, Yamaguchi K, Furukawa Y, Doki N, Eto K, Nishikawa K, Ding Y, Myojo T, Harada Y, Harada H, Iwama A. Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome. Nat Commun 2025 Nov 28;16(1):10726. 

2. Vick EJ, Hassan A, Choi K, Bennett J, Muto T, Culvert-Cochran AE, Hueneman K, Bolanos LC, Wunderlich M, Zhang X, McKnight C, Ceribelli M, Klumpp-Thomas C, Greis K, Thomas CJ,  Starczynowski DT. Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in myeloid malignancies via c-Myc destabilization. Leukemia. 2025 Sep;39(9):2163-2173. 

3. Yamauchi H, Oishi A, Ajiro M, Nakayama A, Nishimura K, Kurikawa M, Yoshida M, Kudo R, Koizumi M, Izumi-Tamura T, Nagase M, Shinohara N, Hanzawa M, Sakumoto M, Nishino T, Maenosono R, Kawachi A, Mukohyama J, Yano S, Muto T, Yoshimi A. Dual compartment utility of BRET-based biosensors for PPP2R5A/B56α, a cancer-associated B regulatory subunit of PP2A. Biotechniques. 2025 Apr;77(4):153-163.

2024

1. Matsui S, Ri C, Bolanos L, Choi K, Shibamiya A, Ishii A, Takaishi K, Oshima- Hasegawa N, Tsukamoto S, Takeda Y, Mimura N, Yoshimi A, Yokote K, Starczynowski D, Sakaida E, Muto T*, Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia. 2024 May;38(5):1032-1045.  *Corresponding author 

2023

1. Muto T*, Walker C, Agarwal P, Vick E, Sampson A, Choi K, Niederkorn M, Ishikawa C, Hueneman K, Varney M *Starczynowski D. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica. 2023 Oct 1;108(10):2715-2729.  *Corresponding author

2022

1. Isshiki Y, Oshima M, Mimura N, Kayamori K, Miyamoto-Nagai Y, Seki M, Nakajima-Takagi Y, Kanamori T, Iwamoto E, Muto T, Tsukamoto S, Takeda Y, Ohwada C, Misawa S, Ikeda JI, Sanada M, Kuwabara S, Suzuki Y, Sakaida E, Nakaseko C, Iwama A. Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis. JCI Insight. 2022 Oct 24;7(20). 

2. Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, Bolanos LC, Christie S, Smith MA, Niederkorn M, Muto T, Kesari S, Garrett-Bakelman FE, Bartholdy B, Will B, Weirauch MT, Mulloy JC, Gul Z, Medlin S, Kovall RA, Melnick AM, Perentesis JP, Greis KD, Nurmemmedov E, Seibel WL, Starczynowski DT. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Sci Transl Med. 2022 Mar 9;14(635):eabb7695. 

3. Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, Lasry A, Redondo L, Choi K, Gong Y, Walker C, Heneman K, Bolanos L, Barreyro L, Lee L, Greis K, Vasyliev N, Jamayran A, Nudler E, Lowe A, Aifantis I, Starczynowski T, TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022 Feb 3;29(2):298-314.e9. 

2020

1. Muto T, Walker S, Choi K, Hueneman K, Gul Z, Garcia-Manero G, Ma A, Zheng Y, Starczynowski DT. Adaptive response of MDS cells to the inflammatory milieu contributes to sustained myeloid expansion and a competitive advantage. Nature Immunol. 2020 May;21(5):535-545.

2018

1. Fang J#, Muto T#, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, Starczynowski DT, TRAF6 mediates basal activation of NF-kB necessary for hematopoietic stem cell homeostasis. Cell Rep. 2018 Jan 30;22(5):1250-1262.　#Co-first author

2017

1. Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia. 2017 Apr;31(4):861-871.

2016

1. Shimizu R, Muto T*, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri-Manako C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Iseki T, Starczynowski DT, Iwama A, Yokote K, Nakaseko C. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leuk Res. 2016 Nov;50:85-94.  *Corresponding author

2015

1. Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, and Iwama A. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-depenedent manner. Blood. 2015 Sep 3;126(10):1172-83.

2. Muto T, Sashida G, Hasegawa N, Nakaseko C, Yokote K, Shimoda K, Iwama A. MDS with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice. Leuk Lymphoma. 2015 Feb;56(2):520.

2014

1. Sashida G, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto T, Inaba T, Koseki H, Huang G, Kitamura T, Iwama A. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukemic transformation. Nat Commun. 2014 Jun 23;5:4177.

2013

1. Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med. 2013 Nov 18;210(12):2627-39.